303 Wyman Street
2 articles with Adagio Therapeutics
Adagio Therapeutics, Inc., a biotechnology company developing best-in-class antibodies to broadly neutralize coronaviruses, today announced that Tillman Gerngross, Ph.D., chief executive officer, and Jane Henderson, chief financial officer, will participate in one-on-one investor meetings during the Cowen 41st Annual Health Care Conference on Monday, March 1, 2021.
Adagio Therapeutics Announces Dosing of First Patient in Phase 1 Trial of ADG20, its Lead Monoclonal Antibody Candidate for the Treatment and Prevention of COVID-19
-ADG20 is uniquely engineered to maximize potency, duration of effect, and ease of use in the community setting, and has shown outstanding manufacturability to meet global demand-